Phase 2a trial designed to investigate the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules SASKATOON, SK, Aug. 26, 2025 /PRNewswire/ - ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today announced the activation of the Centre Hospitalier de l'Université de Montréal ("CHUM") as first clinical site in its Phase 2a UTOPIA-1 (U ...